File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Surpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia

TitleSurpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia
Authors
Mesa, RAKomatsu, NSingh, GHHJin, JLee, SEHou, HASato, TQin, AUrbanski, RShih, WZagrijtschuk, CZimmerman, CVerstovsek, S
Issue Date2021
PublisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
Citation
2021 American Society of Hematology (ASH) 63rd Meeting & Exposition, Atlanta, Georgia, USA, 10-14 December 2021. In Blood, v. 138 n. Suppl. 1, abstract no. 1491 How to Cite?
DOI: http://dx.doi.org/10.1182/blood-2021-147417
Description634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I - abstract no. 1491
Persistent Identifierhttp://hdl.handle.net/10722/309331
ISSN
0006-4971
2023 Impact Factor: 21.0
2023 SCImago Journal Rankings: 5.272
ISI Accession Number ID
WOS:000736398805215

 

DC FieldValueLanguage
dc.contributor.authorMesa, RA-
dc.contributor.authorKomatsu, N-
dc.contributor.authorSingh, GHH-
dc.contributor.authorJin, J-
dc.contributor.authorLee, SE-
dc.contributor.authorHou, HA-
dc.contributor.authorSato, T-
dc.contributor.authorQin, A-
dc.contributor.authorUrbanski, R-
dc.contributor.authorShih, W-
dc.contributor.authorZagrijtschuk, C-
dc.contributor.authorZimmerman, C-
dc.contributor.authorVerstovsek, S-
dc.date.accessioned2021-12-29T02:13:34Z-
dc.date.available2021-12-29T02:13:34Z-
dc.date.issued2021-
dc.identifier.citation2021 American Society of Hematology (ASH) 63rd Meeting & Exposition, Atlanta, Georgia, USA, 10-14 December 2021. In Blood, v. 138 n. Suppl. 1, abstract no. 1491-
dc.identifier.issn0006-4971-
dc.identifier.urihttp://hdl.handle.net/10722/309331-
dc.description634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I - abstract no. 1491-
dc.languageeng-
dc.publisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/-
dc.relation.ispartofBlood-
dc.relation.ispartof2021 American Society of Hematology (ASH) 63rd Meeting & Exposition-
dc.titleSurpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia-
dc.typeConference_Paper-
dc.identifier.emailSingh, GHH: gillhsh@hku.hk-
dc.identifier.authoritySingh, GHH=rp01914-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1182/blood-2021-147417-
dc.identifier.hkuros331294-
dc.identifier.volume138-
dc.identifier.issueSuppl. 1-
dc.identifier.spage1491-
dc.identifier.epage1491-
dc.identifier.isiWOS:000736398805215-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats